Hericium erinaceus strain, culture method thereof, hericium erinaceus-ginseng bidirectional solid fermentation method and method for high-efficiency conversion of rare ginsenosides

Abstract

This invention relates to the field of fermentation technology, and particularly to a Hericium erinaceus strain and its cultivation method, a Hericium erinaceus-ginseng two-way solid-state fermentation method, and a method for efficiently converting rare ginsenosides. The Hericium erinaceus strain has the preservation number CGMCC No. 22450. The Hericium erinaceus strain of this invention can efficiently convert rare ginsenosides from ginseng.

Description

[0001] This application is a divisional application of the invention filed on July 13, 2021, entitled "Hericium erinaceus strain and its cultivation method, Hericium erinaceus-ginseng bidirectional solid fermentation method and efficient conversion method of rare ginsenosides", with application number 202110789327.1. Technical Field

[0002] This invention relates to the field of fermentation technology, and in particular to Hericium erinaceus strains and their cultivation methods, Hericium erinaceus-ginseng two-way solid-state fermentation method, and method for efficiently converting rare ginsenosides. Background Technology

[0003] Ginseng (Panax ginseng CAMey) is a perennial, shade-loving dicotyledonous herb, a traditional and precious Chinese medicinal herb, mainly produced in Northeast my country, and hailed as the "King of Herbs." According to the Chinese Pharmacopoeia, ginseng possesses multiple medicinal effects, including greatly replenishing vital energy, restoring pulse and consolidating the body, and calming the mind. Studies have shown that the pharmacological activity of ginseng mainly depends on ginsenosides and rare ginsenosides such as Rd, Rg1, Rg3, Rh1, and Rh2. However, these natural saponins are present in extremely low quantities, and their extraction and separation are complex with very low yields, making industrial production impossible. Therefore, converting ginsenosides into rare saponins is of profound significance.

[0004] Ginseng solid-state fermentation technology uses ginseng or its residue as a medicinal matrix. Through the rich enzyme system of microorganisms, cellulose substances in the medicinal matrix are hydrolyzed, providing energy for the microorganisms' growth and metabolism. The physiological metabolic activities and biochemical reactions of the microorganisms modify the structure of ginsenosides, resulting in new bioactive components and new pharmacological effects. This microbial transformation can rapidly and effectively alter the sugar chain structure of saponins, converting proto-ginsenosides into rarer ginsenosides and enhancing their bioactivity. For example, *Lactobacillus plantarum* KCCM 11613P can convert ginsenosides Rb2 and Rb3 into ginsenoside Rd, while *Bifidobacterium lactis* Bi-07 and *Lactobacillus rhamnosus* HN001 can convert ginsenosides Rb1, Rc, and Rb2, yielding specifically deglycosylated ginsenoside Rd as the final metabolite. Hasegawa et al. used the strain Prevotella oris, isolated and screened from intestinal anaerobic microorganisms, to convert various ginsenosides (such as Rb1, Rc, Rd, etc.) into rare ginsenoside components. Qin et al. used β-glucosidase to convert diol-type ginsenoside Rb1 into the rare ginsenoside CK in Paecilomyces Bainier sp. 229. Choi, from a protein engineering perspective, used specific enzymes in microorganisms to hydrolyze specific glycosides bound to ginsenosides to convert ginsenoside Rc into the rare ginsenoside CK.

[0005] Ginseng medicinal materials that have undergone microbial solid-state fermentation produce fermentation products that are more easily digested and absorbed by the human body, reducing the original toxicity of the medicinal materials while significantly increasing their medicinal value. For example, rare ginsenosides Rg2 and Rg3, which are derived from proto-ginsenosides, have more potent anti-anxiety, anti-inflammatory, and anti-cancer activities, while rare ginsenosides CK and F... 12 It exhibits excellent pharmacological activity in many aspects, including anti-tumor, anti-mutagenic, anti-inflammatory, liver-protective, and asthma-relieving effects, and has higher pharmacological activity compared to the original ginsenosides. Wang Hongfeng et al., in their study of the chemical composition changes during the two-way solid-state fermentation of ginseng, discovered a large number of rare ginsenosides in the ginseng medicinal microorganisms, and speculated that ginsenosides Rg1, Re, and Rb may be transformed into rare ginsenosides Rg3, Rh, etc. Compared to chemical transformation methods, this two-way fermentation biotransformation technology can significantly improve transformation efficiency without producing harmful byproducts. For example, ginsenoside Rd is deglycosylated into a large number of rare ginsenosides.

[0006] Hericium erinaceus, belonging to the phylum Basidiomycota, class Agaricomycetes, order Russulales, family Hericiaceae, and genus Hericium, is an annual fruiting body. It is sessile or has a very short lateral stalk as described in literature. When fresh, it is fleshy, later becoming leathery, odorless and tasteless, and when dried, it becomes cheese-like or corky, with a slightly sour taste. During its growth, it produces secondary metabolites such as steroidal compounds, alkaloids, aromatic compounds, terpenes, fatty acids, and lipids, which possess certain antioxidant, antibacterial, anti-aging, antitumor, neuroprotective, and anti-inflammatory effects. The potential medicinal value of these secondary metabolites has also attracted considerable attention.

[0007] Many microorganisms in nature can grow on solid substrates, especially filamentous fungi, which can grow in the absence of water and adhere to solid medicinal substrates. Hericium erinaceus, a valuable large medicinal and edible fungus, can undergo bidirectional fermentation with solid substrates such as medicinal materials or residues. During solid-state fermentation, various secondary metabolites produced by the fungus can modify the material basis of the solid substrate, thereby increasing the content of active substances in the substrate. For example, Liu Mingming et al. used Hericium erinaceus to ferment wheat on a solid culture medium and found that, compared with the control group, the Hericium erinaceus fermentation group significantly increased the protein content in the wheat substrate. After fermentation of Hericium erinaceus with soybean on a solid culture medium, the contents of total flavonoids and total triterpenes decreased, while the contents of total polyphenols and anthocyanins increased. Sheng Yue used Hericium erinaceus to ferment corn gluten meal and found that the antioxidant activity of the fermentation products was significantly increased.

[0008] The solid-state fermentation process of Hericium erinaceus mimics the living conditions of many higher filamentous fungi. In this process, Hericium erinaceus can enhance the pharmacological activity of fermentation products by altering the composition and structure of active substances. Compared to fungal spores produced by liquid fermentation, the enzymes, fungal spores, and metabolites produced under solid-state fermentation conditions exhibit stronger environmental adaptability. Previous studies have found that spores produced by solid-state fermentation of Hericium erinaceus are more stable, have stronger resistance to drying, and exhibit a higher germination rate over a longer period after freeze-drying.

[0009] Ginseng contains a high concentration of saponins such as Rb1, Rb2, Rc, Rd, Re, and Rg1. Rare ginsenosides, such as F1, F2, Rg3, Rh1, Rh2, CK, CY, and CMc, are present in very low amounts in natural ginseng but often exhibit better pharmacological activity. Since rare ginsenosides share the same core structure as high-concentration saponins, differing only in the number of sugar residues, they can be prepared by hydrolyzing the sugar residues in high-concentration saponins. Common methods include acid hydrolysis, high-temperature and high-pressure (HTHP), microbial transformation, and enzymatic transformation. Chemical methods such as acid hydrolysis and HTHP are limited in their development and application due to their harsh reaction conditions, low conversion efficiency, numerous byproducts, and difficulties in separation and purification. Biotransformation, on the other hand, has become the most promising method due to its mild reaction conditions, high conversion efficiency, and good specificity, and significant progress has been made in this field both domestically and internationally. Biotransformation generally includes microbial transformation and enzymatic transformation.

[0010] The microorganisms currently mainly used for ginsenoside conversion are as follows:

[0011] 1. Human gut bacteria, including *Bacillus*, *Bifidobacterium*, *Clostridium*, and *Lactobacillus*, have attracted widespread attention from researchers due to their ability to metabolize orally ingested ginsenosides, which are then safely used in food. These microorganisms can grow in anaerobic environments using ginsenosides as a carbon source. However, using gut bacteria to convert ginsenosides also presents challenges such as high culture medium costs and low yields.

[0012] 2. Microorganisms isolated from ginseng cultivation soil include fungi such as *Curvularia crescentis*, *Aspergillus rhizogenes*, *Pterococcus cyanidus*, *Fusarium canis*, *Apertoire erectum*, and *Penicillium*, and bacteria such as *Bacillus megaterium*, *Sphingomonas sphingolipidae*, *Stenosporium*, *Mesocystis*, and *Bacteroides*. Both fungi and bacteria have been used to transform ginsenosides. Compared to intestinal bacteria, soil microorganisms can grow rapidly in ordinary culture media, giving them a significant economic advantage in ginsenoside transformation. However, soil microorganisms must be identified as safe before they can be used in the food industry. Although non-pathogenic microorganisms can be used in the food industry, microbial transformation methods still suffer from poor selectivity, low yields, and the enzymes secreted by microorganisms involved in degradation are difficult to determine.

[0013] There are also traditional Chinese medicines such as red yeast rice, mulberry fungus, and Lactobacillus plantarum and yeast that are used for fermentation and transformation. Currently, bacteria, yeast and mold are mainly used for the biotransformation of ginsenosides. There is no research on the application of two-way solid-state fermentation technology to co-ferment and transform rare ginsenosides with Hericium erinaceus strain and ginseng. Summary of the Invention

[0014] In view of this, the present invention provides a Hericium erinaceus strain and its cultivation method, a Hericium erinaceus-ginseng two-way solid-state fermentation method, and a method for efficiently converting rare ginsenosides. This Hericium erinaceus strain can efficiently convert rare ginsenosides from ginseng.

[0015] To achieve the above-mentioned objectives, the present invention provides the following technical solution:

[0016] This invention provides a strain of Hericium erinaceus, with the preservation number CGMCC No. 22450.

[0017] The present invention also provides a method for culturing the Hericium erinaceus strain, comprising the following steps:

[0018] The Hericium erinaceus strain was revived and inoculated onto slant culture medium for slant culture.

[0019] The Hericium erinaceus strain cultured on slant culture was inoculated into primary liquid medium for primary seed culture.

[0020] The Hericium erinaceus strains after primary seed culture were inoculated into secondary liquid culture medium for secondary seed culture.

[0021] Preferably, the slant culture medium is PDA solid culture medium.

[0022] Preferably, the temperature for slant culture is 24–28℃, and the time is 5–20 hours.

[0023] In a specific embodiment provided by the present invention, the temperature for slant culture is 26°C.

[0024] As a preferred option, the formulation of the primary liquid culture medium is: 10-30g glucose, 5-15g peptone, 1-5g KH2PO4, 0.5-1.5g MgSO4·7H2O, and 1L water;

[0025] As a preferred method, the conditions for primary seed culture are: 24–28℃, 150–200 rpm / min, dark conditions, and culture for 10–20 days.

[0026] In a specific embodiment provided by the present invention, the formula of the primary liquid culture medium is: 20g glucose, 10g peptone, 2g KH2PO4, 1g MgSO4·7H2O, and 1L water.

[0027] In a specific embodiment provided by the present invention, the conditions for primary seed culture are: 26℃, 160rpm / min, dark conditions, culture for 15 days.

[0028] As a preferred option, the formulation of the secondary liquid culture medium is: 20-30g glucose, 0.1-0.5g peptone, 0.1-0.5g yeast extract, 2-8g KH2PO4, 0.5-1.5g MgSO4·7H2O, and 1L water;

[0029] As a preferred method, the secondary seed culture is carried out at a temperature of 24–28℃, a speed of 150–200 rpm / min, in the dark, for 5–10 days.

[0030] As a preferred option, the inoculation amount of Hericium erinaceus strains after primary seed culture is 1:(10-30)(V / V).

[0031] In a specific embodiment provided by the present invention, the inoculation amount of the Hericium erinaceus strain after primary seed culture is 1:20 (V / V).

[0032] In a specific embodiment provided by the present invention, the formula of the secondary liquid culture medium is: 22g glucose, 0.2g peptone, 0.2g yeast powder, 5g KH2PO4, 1g MgSO4·7H2O, and 1L water;

[0033] In a specific embodiment provided by the present invention, the conditions for secondary seed culture are: 26℃, 160rpm / min, dark conditions, culture for 7 days.

[0034] This invention also provides a method for two-way solid-state fermentation of Hericium erinaceus and ginseng, comprising the following steps:

[0035] Ginseng powder is mixed with water and sterilized to obtain a ginseng medicinal matrix;

[0036] Hericium erinaceus strains were inoculated into ginseng substrate and fermented.

[0037] Preferably, the mass percentage of water to ginseng powder is 30% to 50%.

[0038] In a specific embodiment provided by the present invention, the mass percentage of water to ginseng powder is 40%.

[0039] Preferably, the fineness of the ginseng powder is 10-20 mesh.

[0040] Preferably, sterilization is performed by high-temperature, high-pressure sterilization and / or ultraviolet sterilization.

[0041] As a preferred option, the inoculation amount of Hericium erinaceus strain is 10%–30% (W / V) of secondary Hericium erinaceus seed culture solution.

[0042] In a specific embodiment provided by the present invention, the inoculation amount of Hericium erinaceus strain is 20% (W / V) of secondary Hericium erinaceus seed culture medium.

[0043] As a preferred method, the fermentation conditions are: temperature of 23–28℃ and time of 30–50 days.

[0044] After solid-state fermentation, the co-fermentation product (ginseng medicinal microbial material) obtained can be made into products with similar effects to ginseng and monkey head mushroom (pharmaceuticals, health products, functional foods, and foods), such as tablets, granules, effervescent tablets, pills, and oral liquids.

[0045] The present invention also provides mycelium obtained by the above-mentioned Hericium erinaceus-ginseng two-way solid-state fermentation method.

[0046] The present invention also provides a food product comprising the above-mentioned microbial material and food-grade excipients.

[0047] This invention also provides a method for efficiently converting rare ginsenosides Rg3 and Rh1, comprising the following steps:

[0048] Ginseng powder is mixed with water and sterilized to obtain a ginseng medicinal matrix;

[0049] Hericium erinaceus strains were inoculated into ginseng substrate, fermented, and purified to obtain Rg3 and Rh1.

[0050] This invention provides a Hericium erinaceus strain and its cultivation method, a Hericium erinaceus-ginseng two-way solid-state fermentation method, and a method for efficiently converting rare ginsenosides. The Hericium erinaceus strain has the preservation number CGMCC No. 22450. This invention has the following advantages:

[0051] 1. Hericium erinaceus is a traditional Chinese medicinal and edible fungus with the functions of benefiting the five internal organs and strengthening the spleen and stomach. As a food and medicine, it must be safe and effective. This invention has discovered and cultivated a wild strain CCUCM-HE-001 that can transform rare ginsenosides in ginseng.

[0052] 2. This invention is the first to utilize Hericium erinaceus and 4-year-old ginseng for two-way solid-state fermentation to increase the content of rare ginsenosides Rg3 and Rh1. This research has not been reported before.

[0053] 3. The process of this invention can efficiently convert rare ginsenosides Rg3 and Rh1.

[0054] Biological Preservation Instructions

[0055] CCUCM-HE001, classified and named as Hericium erinaceus, was deposited on June 10, 2021, at the China General Microbiological Culture Collection Center (CGMCC), located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, with accession number CGMCC No. 22450. Attached Figure Description

[0056] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the accompanying drawings used in the description of the embodiments or the prior art will be briefly introduced below.

[0057] Figure 1 Colony morphology of strain CCUCM-HE-001;

[0058] Figure 2 Mycelial morphology of strain CCUCM-HE-001;

[0059] Figure 3 ITS phylogenetic tree of strain CCUCM-HE001;

[0060] Figure 4 Comparison of ginsenoside content between diol-type and oleanolic acid-type ginsenosides; Note: *** represents a highly significant difference compared to day 0 (P < 0.001); ### represents a highly significant difference between fermentation days 30 and 40 (P < 0.001).

[0061] Figure 5 Comparison of triol-type ginsenoside content; Note: *** represents a highly significant difference compared to day 0 (P < 0.001); ** represents a significant difference compared to day 0 (P < 0.005); ### represents a highly significant difference between fermentation days 30 and 40 (P < 0.001). Detailed Implementation

[0062] This invention discloses a Hericium erinaceus strain and its cultivation method, as well as a Hericium erinaceus-ginseng two-way solid-state fermentation method. Those skilled in the art can refer to the content of this document and appropriately modify the process parameters to achieve the desired results. It is particularly important to note that all similar substitutions and modifications are obvious to those skilled in the art and are considered to be included in this invention. The methods and applications of this invention have been described through preferred embodiments. Those skilled in the art can clearly modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit, and scope of this invention to realize and apply the technology of this invention.

[0063] The culture media and reagents used in this invention are all commercially available.

[0064] The present invention will be further illustrated below with reference to the embodiments:

[0065] Example 1: Identification of Hericium erinaceus strain

[0066] 1. Culture and morphological identification of Hericium erinaceus strain

[0067] The strain CCUCM-HE001 was inoculated onto PDA plates and incubated at 28°C for approximately 10 days. Colony growth was observed, and microscopic morphological classification and identification were performed using the solid medium slide method, based on characteristics such as colony color, hyphal growth, and spore morphology. When cultured on PDA medium, the colonies were round with irregular edges. The hyphae were white and fluffy, spreading radially from the inoculation point. Hyphae growth was slow in the early stages, but increased in number in the later stages, producing pigment that turned the medium brownish-yellow. Figure 1 The hyphae are relatively thick, without septa, and the spores are round. Figure 2 ).

[0068] 2. Molecular biological identification

[0069] Homology analysis was performed on the sequenced sequences, and a phylogenetic tree was constructed. The sequencing results and phylogenetic tree results are shown below. The ITS region of the genomic DNA of strain CCUCM-HE001 is 606 bp in length. Online alignment using the BLAST database in NCBI's GenBank database showed that strain CCUCM-HE-001 has a sequence similarity of over 99% with *Hericium erinaceum*. A phylogenetic tree was constructed using sequences with high similarity to the strain to further determine the species relationship of this fungus. Using *Mycoleptodonoides aitchisonii* as the exogenous strain, the phylogenetic tree was constructed by pairwise comparison of the fungal sequences using the Neighbour-Joining method, calculating the evolutionary or phylogenetic relationships between the sequences, as shown below. Figure 3 As shown in the figure. The phylogenetic tree constructed by ITS sequence comparison analysis showed that strain CCUCM-HE001 had a high homology and close phylogenetic relationship with Hericium erinaceum, indicating that strain CCUCM-HE001 belongs to Hericium erinaceum.

[0070] Example 2: Hericium erinaceus-ginseng two-way solid-state fermentation technology

[0071] 1. Slant culture of Hericium erinaceus

[0072] The Hericium erinaceus strain stored at 4°C was revived and transferred to freshly prepared PDA solid medium under aseptic conditions. It was then cultured in a 26°C incubator in the dark for 7 days. The culture was then subcultured again, and the above steps were repeated. Once the Hericium erinaceus mycelium growth covered the entire surface of the medium, liquid culture could be carried out.

[0073] 2. Preparation of primary and secondary Hericium erinaceus liquid inoculum

[0074] Take an appropriate amount of the above-mentioned Hericium erinaceus solid culture and inoculate it into primary liquid culture medium (20g glucose, 10g peptone, 2g KH2PO4, 1g MgSO4·7H2O, 1L distilled water). Incubate for 15 days in the dark at 26℃ and 160rpm / min. Then, transfer the primary liquid culture to secondary liquid culture medium of Hericium erinaceus at a ratio of 1:20 (V / V) (22g glucose, 0.2g peptone, 0.2g yeast extract, 5g KH2PO4, 1g MgSO4·7H2O, 1L distilled water). Incubate for 7 days under the above conditions. When the secondary shake flask is observed to be covered with uniformly shaped pale yellow mycelial balls, stop the fermentation.

[0075] Example 3: Preparation of Hericium erinaceus-ginseng dual solid-state fermentation mycelium

[0076] The optimized conditions in the references (Chen Tianli. Preparation process and antitumor activity study of compound ginseng and herb mycotoxin granules [D]. Changchun University of Traditional Chinese Medicine, 2019; Tan Yanqi. Study on the effect of solid-state fermentation conditions of Cordyceps militaris on the content of main active ingredients [D]. Hunan Agricultural University, 2013.) were used to carry out bidirectional solid-state fermentation of ginseng and Hericium erinaceus. Ginseng was pulverized and passed through a 16-mesh pharmacopoeia sieve to obtain ginseng powder with uniform particle size. 30g of the above ginseng powder was weighed and placed in a 200mL culture flask. 40% distilled water was added as the initial water volume. After the water and ginseng powder were mixed evenly, the mixture was placed in the culture flask and sterilized twice at 121℃ for 30 minutes each time. The sterilized ginseng medicinal material matrix was transferred to aseptic conditions, cooled, and then shaken to loosen it. It was then sterilized under ultraviolet light for 30 minutes. The experimental group consisted of ginseng solid culture medium inoculated with 20% (w / v) secondary Hericium erinaceus seed culture solution, while the control group consisted of ginseng solid culture medium without secondary Hericium erinaceus seed culture solution. Fermentation ended (30 days) when Hericium erinaceus mycelia completely covered the entire culture flask and formed distinct primordia structures, followed by an additional 10 days of fermentation. Every 3 days, three flasks from each of the experimental and control groups were removed, dried at 40℃, pulverized, passed through a No. 3 sieve, and stored in a sealed container away from light.

[0077] Example 4: UPLC-QQQ-MS / MS technology was used to analyze and monitor the changes in the content of 13 ginsenosides in Hericium erinaceus-ginseng mycelium.

[0078] 1. Preparation of reference solution

[0079] Accurately weigh appropriate amounts of ginsenoside reference standards Rb1, Rb2, Rc, Rd, Re, Rf, Rg1, Rg2, Rg3, F2, F3, Rh1, and Ro, dissolve them in chromatographic methanol to prepare a mixed reference solution, shake well, and filter through a 0.22 μm organic filter membrane for later use. Store the above mixed reference solution in a refrigerator at 4°C for later use.

[0080] 2. Preparation of the test solution

[0081] According to the method in the Chinese Pharmacopoeia, accurately weigh 1.0 g of bacterial material, wrap it in filter paper, place it in a Soxhlet extractor, add chloroform and heat under reflux for 3 hours, discard the chloroform solution, remove the residue packet, evaporate the solvent, transfer the filter paper packet to a 100 mL stoppered conical flask, add 50 mL of water-saturated n-butanol, seal tightly and let stand overnight, sonicate (power 250 W, frequency 50 kHz) for 30 min, filter, discard the initial filtrate, accurately measure 25 mL of the subsequent filtrate, evaporate to dryness in an evaporating dish, dissolve the residue in methanol and transfer it to a 5 mL volumetric flask, dilute with methanol to the mark, shake well, filter through a 0.22 μm organic filter membrane, and store in a refrigerator at 4 °C for later use.

[0082] 3. Liquid Chromatography Separation Conditions

[0083] Thermo C 18 The chromatographic column (50 mm × 3 mm, 1.7 μm) was used with a mobile phase of 0.1% formic acid (A)-acetonitrile (B) and gradient elution: 0–5 min, 19% B; 5–29 min, 19%–25% B; 29–72 min, 25%–40% B; 72–77 min, 40%–90% B; 77–80 min, 90% B; 80–83 min, 90%–19% B; 83–88 min, 19% B; flow rate 0.2 mL / min; column temperature 35 °C; sample chamber temperature 4 °C; and injection volume 5 μL.

[0084] 4. Mass spectrometry detection conditions

[0085] Ionization is performed using electrospray ionization in negative ion mode, with full-scan detection by the electrospray ionization source (ESI); mass scan range m / z 100~1500; spray voltage: 2500V; sheath gas pressure: 35arb; auxiliary gas pressure: 10arb; transmission capillary temperature: 350℃; nebulizer temperature: 300℃.

[0086] Experimental Example 1: Determination of Myricetin Content in Hericium erinaceus-Ginseng Mycotoxin

[0087] The ginsenoside content of the fermentation microorganisms at different fermentation stages in Example 3 was determined using the method of Example 4. The peak area was recorded, and the content of 13 saponins was calculated based on the corresponding linear regression equations.

[0088] The saponin content in the mycelium at different fermentation times was determined, and the results are as follows: Figure 4 , 5 As shown in the results, the content of various ginsenosides in ginseng increased and decreased to varying degrees after two-way fermentation. Compared with day 0, when the fermentation reached day 30, the content of rare saponin Rg3 increased by 41.07%, the content of oleanolic acid-type saponin Ro increased by 64.18%, and the content of rare saponin Rh1 increased by 63.57%.

[0089] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. Application of Hericium erinaceus strain in the conversion of ginseng into ginsenosides; The Hericium erinaceus strain has the accession number CGMCC No. 22450; The ginsenosides are one or more of Rg3, Rh1, Rd, Ro, or Rg2.

2. A medicament, characterized by, This includes microbial materials and pharmaceutically acceptable excipients; The method for preparing the microbial substrate includes the following steps: Ginseng powder is mixed with water and sterilized to obtain a ginseng medicinal matrix; The Hericium erinaceus strain with preservation number CGMCC No.22450 was inoculated into the ginseng medicinal material substrate and fermented to obtain the mycelium.

3. A method of converting ginsenoside Rd, Ro or Rg2, characterized in that, Includes the following steps: Ginseng powder is mixed with water and sterilized to obtain a ginseng medicinal matrix; The Hericium erinaceus strain with preservation number CGMCC No.22450 was inoculated into the ginseng medicinal material substrate, fermented, and purified to obtain Rd, Ro or Rg2.

Images